Celldex Therapeutics, Inc. (FRA:TCE2)

Market Cap	1.38B -5.7%
Revenue (ttm)	2.22M -73.9%
Net Income	-191.37M
EPS	-2.88
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	10
Open	21.60
Previous Close	22.20
Day's Range	21.60 - 21.60
52-Week Range	13.20 - 25.40
Beta	n/a
RSI	38.97
Earnings Date	Feb 23, 2026

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, pr...

• Industry: Biological Products, Except Diagnostic Substances
• CEO: Anthony Marucci
• Employees: 186
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TCE2

Financial Performance

In 2024, Celldex Therapeutics's revenue was $7.02 million, an increase of 1.99% compared to the previous year's $6.88 million. Losses were -$157.86 million, 11.6% more than in 2023.

Financial numbers in USD